Table 2 Percentages of galcanezumab- versus placebo-treated patients who shifted from CM to EM frequency

Shift to EM frequency

Placebo

511

216

42.3

39.7 (2.7)

(34.5, 45.1)

101

19.8

16.7 (1.8)

(13.5, 20.4)

Galcanezumab 120 mg

263

147

55.9

53.9 (3.6)

(46.8, 60.9)

1.8

(1.3, 2.5)

< 0.001

90

34.2

29.9 (3)

(24.3, 36.2)

2.1

(1.5, 3)

< 0.001

Galcanezumab 240 mg

267

134

50.2

47.1 (3.6)

(40.1, 54.2)

1.4

(1.0, 1.9)

0.065

77

28.8

24.3 (2.8)

(19.3, 30.1)

1.6

(1.1, 2.3)

0.008

Galcanezumab pooled

530

281

53.0

50.5 (2.8)

(45.1, 55.9)

1.6

(1.2, 2.0)

0.001

167

31.5

27.1 (2.2)

(22.9, 31.6)

1.9

(1.4, 2.5)

< 0.001

Shift to LFEM frequency

Placebo

511

111

21.7

17.8 (2.0)

(14.1, 22.1)

28

5.5

4.3 (0.8)

(3.0, 6.2)

Galcanezumab 120 mg

263

77

29.3

24.7 (3.0)

(19.3, 31.2)

1.5

(1.1, 2.2)

0.023

32

12.2

9.8 (1.7)

(7, 13.6)

2.4

(1.5, 3.9)

< 0.001

Galcanezumab 240 mg

267

85

31.8

26.8 (3.2)

(21.1, 33.5)

1.7

(1.2, 2.4)

0.004

36

13.5

10.6 (1.7)

(7.7, 14.5)

2.6

(1.6, 4.2)

< 0.001

Galcanezumab pooled

530

162

30.6

25.8 (2.4)

(21.3, 30.8)

1.6

(1.2, 2.2)

0.002

68

12.8

10.2 (1.3)

(7.9, 13.1)

2.5

(1.7, 3.8)

< 0.001

Shift to VLFEM frequency

Placebo

511

45

8.8

6.5 (1.3)

(4.4, 9.5)

9

1.8

1.4 (0.5)

(0.8, 2.7)

Galcanezumab 120 mg

263

29

11.0

7.7 (1.8)

(4.9, 12.0)

1.2

(0.7, 2.0)

0.46

5

1.9

1.5 (0.6)

(0.7, 3.5)

1.1

(0.4, 2.9)

0.912

Galcanezumab 240 mg

267

39

14.6

10.6 (2.2)

(7.1, 15.7)

1.7

(1.1, 2.8)

0.025

8

3

2.2 (0.8)

(1.1, 4.3)

1.6

(0.7, 3.8)

0.318

Galcanezumab pooled

530

68

12.8

9.2 (1.6)

(6.5, 12.9)

1.5

(1, 2.2)

0.069

13

2.5

1.9 (0.5)

(1.1, 3.2)

1.3

(0.6, 2.8)

0.487